RT Journal Article
SR Electronic
T1 From more testing to smart testing: data-guided SARS-CoV-2 testing choices
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20211524
DO 10.1101/2020.10.13.20211524
A1 Janko van Beek
A1 Zsofia Igloi
A1 Timo Boelsums
A1 Ewout Fanoy
A1 Hannelore Gotz
A1 Richard Molenkamp
A1 Jeroen van Kampen
A1 Corine GeurtsvanKessel
A1 Annemiek van der Eijk
A1 David van de Vijver
A1 Marion Koopmans
YR 2020
UL http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211524.1.abstract
AB We present an in-depth analysis of data from drive through testing stations using rapid antigen detection tests (RDT’s), RT-PCR and virus culture, to assess the ability of RDT’s to detect infectious cases. We show that the detection limits of five commercially available RDT’s differ considerably, impacting the translation into the detection of infectious cases. We recommend careful fit-for-purpose testing before implementation of antigen RDT’s in routine testing algorithms as part of the COVID-19 response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded through EU COVID-19 grant RECOVER (grant agreement ID: 101003589).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of leftover diagnostic specimens for assay validation is permitted under Dutch law.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon requestData is available upon requestData is available upon requestData is available upon request